Scientists at Heidelberg University identified a toxic protein complex — formed between NMDA receptors and TRPM4 ion channels — that drives neuronal death in Alzheimer's disease. This "death complex" is present at significantly higher levels in Alzheimer's mice compared to healthy animals.
How it works:
NMDA receptors normally support nerve cell survival when activated at synapses. However, when TRPM4 channels interact with extrasynaptic NMDA receptors, they create a neurotoxic combination that triggers a vicious cycle: amyloid buildup → toxic signaling → neuron death → more amyloid.
The treatment: FP802
FP802 is a "TwinF Interface Inhibitor" — a small molecule that disrupts the deadly protein interaction by binding to the contact surface where TRPM4 connects to NMDA receptors, without shutting down normal brain signaling.
When treated with FP802, Alzheimer's mice showed:
- Preserved cognitive abilities and memory function
- Prevention of synapse loss
- Protected mitochondrial health
- Reduced amyloid-beta plaque formation
- Slowed disease progression overall
This approach fundamentally differs from previous treatment strategies by targeting downstream cell death mechanisms rather than directly removing amyloid plaques. The same mechanism is implicated in ALS, Huntington's, stroke, and traumatic brain injury.